
ARTICLE IN PRESS

Prostate Int xxx (2017) 1-6



Contents lists available at ScienceDirect

Prostate International



journal homepage: https://www.journals.elsevier.com/prostate-international

Review Article

Reporting and ideal testosterone levels in men undergoing androgen deprivation for prostate cancer—time for a rethink?

Sonja Cabarkapa ^a, Marlon Perera ^a, Ken Sikaris ^b, Jonathan S. O'brien ^a, Damien M. Bolton ^{a, b}, Nathan Lawrentschuk ^{a, c, d, *}

^a Department of Surgery, Austin Hospital, University of Melbourne, Melbourne, Australia

^b Department of Pathology, University of Melbourne, Melbourne, Australia

^c Olivia Newton-John Cancer Research Institute, Austin Hospital, Melbourne, Australia

^d Department of Surgical Oncology, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Australia

ARTICLE INFO

Article history: Received 19 February 2017 Received in revised form 1 May 2017 Accepted 18 May 2017 Available online xxx

Keywords: Androgen deprivation Pathology Prostate cancer Prostate-specific antigen Reporting Testosterone

ABSTRACT

Background: This study aims to review current laboratory reporting strategies across Australia and New Zealand with a view to propose a more useful template for reporting serum testosterone in the context of prostate cancer.

Materials and methods: Registered pathology laboratories in Australia and New Zealand were enrolled into the current study. An electronic or a phone survey was utilized to collect data from each participating laboratory. Obtained information included assay utilized, units reported, reference intervals, lowest reported value, and lowest detectable value. To identify recommendations for testosterone testing, a systematic search was performed across Web of Science (including MEDLINE), EMBASE, and Cochrane libraries.

Results: Assessment of national pathology laboratories identified significant heterogeneity in the reporting methods. Reports typically used a "normal healthy male of 35 years of age" as a comparator but did not refer to optimal castrate levels, the lowest level that their assay was able to achieve, nor did they include appended clinical guidelines relating to the prostate cancer patient cohort.

Conclusions: Across Australia and New Zealand, various methods for testing and reporting serum testosterone exist, while international guidelines remain vague. The fashion in which serum testosterone levels are displayed should be re-evaluated to address the relevant clinical population and reflect an agreed-upon castrate threshold in patients undergoing androgen deprivation therapy.

moting this lower threshold.³

© 2017 Asian Pacific Prostate Society, Published by Elsevier Korea LLC. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

However, recent studies have conferred better oncological out-

comes, with an even lower T threshold of 0.7 nmol/L (20 ng/dL).^{3–5}

This has resulted in changes to international guidelines including a

recent statement from the European Association of Urology pro-

levels of T during ADT, the manner in which serum T is reported has

not been re-evaluated in recent times. The absolute values assist in

clinical decision making, underpinning the importance of their ac-

curacy. However, at present, T levels are still reported in the context

of men being assessed for hypogonadism rather than therapeutic

castration. Typical threshold levels for hypogonadism are generally

>12 nmol/L (346 ng/dL),⁶ values that hold little significance in the

setting of ADT (see Fig. 1). Similarities may be drawn in the assess-

ment of biochemical recurrence after definitive treatment for

PC—where accurate prostate-specific antigen (PSA) levels at the

lowest detection points are critical and may affect management.

Despite the identification of the importance of ensuring castrate

1. Introduction

Since the 1940s, serum testosterone (T) has marked the cornerstone of prostate cancer (PC) progression as postulated by Huggins and Hodges,¹ suggesting a direct correlation between high levels of T and PC progression. This highlights the rationale for castration, traditionally surgical, in an attempt to lower serum T and limit PC progression. Over the last 3 decades, androgen deprivation therapy (ADT) has been introduced as an alternative to surgical castration to achieve castration in the treatment of advanced PC.² Historically, the recommended castrate threshold was below 1.7 nmol/L (50 ng/dL), and this value is still referenced by some regulatory authorities and utilized in clinical trials.³

* Corresponding author. Department of Surgery, Austin Health, University of Melbourne, Melbourne, Australia.

E-mail address: lawrentschuk@gmail.com (N Lawrentschuk).

http://dx.doi.org/10.1016/j.prnil.2017.05.003

p2287-8882 e2287-903X/© 2017 Asian Pacific Prostate Society, Published by Elsevier Korea LLC. This is an open access article under the CC BY-NC-ND license (http:// creativecommons.org/licenses/by-nc-nd/4.0/).

Please cite this article in press as: Cabarkapa S, et al., Reporting and ideal testosterone levels in men undergoing androgen deprivation for prostate cancer—time for a rethink?, Prostate Int (2017), http://dx.doi.org/10.1016/j.prnil.2017.05.003

 RTICLE IN PRES

Ducatata Int. (2017) 1 (

PRNIL104 proof **2**0 June 2017 **2**/6

		Prostate Int xxx ((2017) 1–6				
PSA-prostat Req no: Date: Time:	P479691 P03377	15 14/02/15		P488829 07/11/15 08:55	Units	Ref Range	
Testost	ve hormones (serum/plasma <0.4 L ·kers (serum/plasma)	ı)	<0.4 L	<0.4 L	nmol/L	12.0-31.9	
PSA	<pre></pre> <pre< td=""><td>< 0.03</td><td>< 0.03</td><td><0.03</td><td>µg/L</td><td><6.5</td><td></td></pre<>	< 0.03	< 0.03	<0.03	µg/L	<6.5	
CTX P1NP	1,094 62				μg/L μg/L	See-below See-below	
(<35 y.o.) m Lower level	sterome male reference inter- nen. ls are seen with increasing ag erpretaion within the clinical	ge, coexisting il	0	-		0	
CTX-telope	ptide reference ranges:						
	Female		0–49 years) 0–70 years) >70 years)	150-80 50-80 100-100	00		
	Male		0–24 years) 5–70 years) >70 years)	400-90 100-60 100-75	00 00		
Harmonize	d Australian reference interv P1NP reference		11/03/2015	5			
	Female	(2)	0–24 years) 5–49 years) 0–70 years)	15–9 15–1 15–9	70 90		
	Male		>70 years) 0–24 years) 5–70 years) >70 years)	15–1 15–1 15–1 15–1	15 80		
Harmonize	d Australian reference interv	als in use from	ı 11/03/2015	;			
	nology, Austin health (APA). N eong, Dr Marcel Leroi, DR Q L			2741			
Fig.	1. Typical testosterone pathology rep	port. PSA, prostate-	-specific antigen;	Testost, testoste	erone; y.o., ye	ars old.	Q13
n that pertains to the foll	C .		reporting dat directed to a	a were colle senior labor	ected via a ratory staff	current study, and labo phone survey. Question f member, and in the ca	ns were use that
an interval where pos (2) The lowest T level the	s (as an absolute value in pressible). e laboratory is able to detect. ance as to what the level indic		questions we were entered	re sent to the into the surv	em via e-m vey templa	to give a verbal respon hail. The corresponding an hte and returned by e-ma ng laboratory include	nswers nil. Data

(3) Accurate clinical in the form of a clinical note.

Variations as to what levels are considered "ideal" exist among international guidelines. This has prompted the need for advisory offering recommendations on the optimal levels and timing of tests. In this study, we aimed to determine the current standards of Treporting from pathology laboratories across Australia. Further, we aimed to review the current guidelines in T monitoring in the setting of ADT.

2. Materials and methods

2.1. Survey of pathology laboratories

A list of registered pathology laboratories in Australia and New Zealand was obtained from business listings and the register at the Royal College of Pathologists of Australasia. Laboratories were following: laboratory information (region/city) and T testing information (manufacturer and analyzer utilized, T assay utilized, T units reported, T reference intervals, lowest reported T value, and lowest detectable T value). In addition to this laboratory-specific data, the awareness of T-lowering medication and reporting standards in this population were assessed.

2.2. Construction of a clinical reporting guideline to be issued with reports of serum T

We performed a systematic search to identify all locoregional reporting guidelines for T. Specifically, we aimed to identify articles that outlined the reporting strategies and recommended frequency of T in patients on ADT. To obtain relevant articles, we systematically searched Web of Science (including MEDLINE), EMBASE, and Cochrane. The following search terms were used: "prostate cancer"

Please cite this article in press as: Cabarkapa S, et al., Reporting and ideal testosterone levels in men undergoing androgen deprivation for prostate cancer-time for a rethink?, Prostate Int (2017), http://dx.doi.org/10.1016/j.prnil.2017.05.003

Download English Version:

https://daneshyari.com/en/article/8829063

Download Persian Version:

https://daneshyari.com/article/8829063

Daneshyari.com